Gonadorelin
- Category
- Hormone & Sexual Health
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A synthetic form of GnRH, well studied for triggering LH and FSH release to induce ovulation and test pituitary function. Its trendy longevity-clinic use, preserving testicular function during TRT, is speculative and unproven in humans. The key risk is dosing: continuous, non-pulsatile use paradoxically shuts down the axis it's meant to stimulate, and rare anaphylaxis is reported. Not FDA-approved for that use; supply is compounded or research-grade.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Gonadorelin is a synthetic peptide that is identical to your body's own gonadotropin-releasing hormone (GnRH), the 10-amino-acid master signal that controls reproductive hormone production. It acts on the pituitary gland to stimulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Originally sold as Factrel and Lutrepulse (both now discontinued in the US), gonadorelin has re-emerged as a compounded medication, particularly as a replacement for HCG in testosterone replacement therapy protocols after the FDA reclassified HCG as a biologic in 2020.
How it works in the body
A synthetic version of gonadotropin-releasing hormone (GnRH). It binds to GnRH receptors on pituitary gonadotroph cells, triggering the release of LH and FSH. These hormones then stimulate the gonads to produce testosterone (men) or estrogen and progesterone (women), maintaining natural hormonal feedback.
Research overview
Gonadorelin is one of the best-characterized peptide hormones in medicine, with decades of research dating back to the Nobel Prize-winning work of Andrew Schally and Roger Guillemin in the 1970s. It has a very short half-life of about 2-4 minutes in the bloodstream, meaning it must be given in pulses to mimic the body's natural signaling rhythm. Clinical evidence strongly supports its ability to induce ovulation in women with hypothalamic amenorrhea (91-96% success rate) and to stimulate sperm production in men with congenital hormone deficiencies. Its newer role as an HCG alternative during testosterone therapy has less robust evidence, with mixed results regarding its ability to preserve testicular function and fertility while on exogenous testosterone.
Who researches Gonadorelin?
Commonly researched by
People exploring hormone and sexual health
Researched for effects on hormone levels, sexual function, or fertility.
People researching stimulates endogenous lh and fsh production
One of the primary studied benefits of Gonadorelin.
Important considerations for
Those with Hormone-sensitive cancers (prostate, breast)
HighInitial LH/FSH surge can temporarily increase sex hormone levels before suppression.
Those who are pregnant or breastfeeding
AbsoluteCan disrupt pregnancy hormones.
Safety & interactions
Do not use if
Hormone-sensitive cancers (prostate, breast)
HighInitial LH/FSH surge can temporarily increase sex hormone levels before suppression.
General cautions
Pregnancy
AbsoluteCan disrupt pregnancy hormones.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(13)
Rated by level of concern
Headache, nausea, lightheadedness, and abdominal discomfort (uncommon)
LowFactrel labeling — https://www.rxlist.com/factrel-drug.htm
Injection site reactions including pain, swelling, induration, and pruritus
LowLutrepulse product monograph, adverse reactions — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf ; Factrel labeling — https://www.rxlist.com/factrel-drug.htm (induration at injection site)
Hypersensitivity/anaphylactic reactions (rare but reported; caution on re-administration)
ModerateFactrel labeling — https://www.rxlist.com/factrel-drug.htm ; Lutrepulse product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (frequency categories)
Flushing and tachycardia (rare)
LowFactrel labeling — https://www.rxlist.com/factrel-drug.htm ; Lutrepulse product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf
Bronchospasm (rare)
LowFactrel labeling — https://www.rxlist.com/factrel-drug.htm ; Lutrepulse product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf
Multiple pregnancy risk when used for ovulation induction (12% incidence in clinical trials)
HighLutrepulse product monograph, adverse reactions — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (11/89 = 12%)
Ovarian hyperstimulation syndrome (rare, especially with concurrent clomiphene)
LowLutrepulse product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (1/268, clomiphene co-treatment, <1%)
Antibody formation with repeated administration (rare)
LowLutrepulse product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (~3% with SC FACTREL) ; Factrel labeling — https://www.rxlist.com/factrel-drug.htm (antibody formation after chronic administration)
Risk of pituitary apoplexy if administered to patients with undiagnosed pituitary adenoma
LowFactrel labeling — https://www.rxlist.com/factrel-drug.htm (pituitary apoplexy/sudden blindness as a rare case report)
Menorrhagia (frequency unknown)
TheoreticalAuthorized UK gonadorelin product information, section 4.8, lists menorrhagia with frequency unknown: https://www.medicines.org.uk/emc/product/4853/smpc
Paradoxical pituitary downregulation with continuous (non-pulsatile) high-dose administration
HighLutrepulse product monograph, overdosage/pharmacology — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (continuous non-pulsatile exposure can temporarily reduce pituitary responsiveness). Prior apoplexy PubMed link removed - it did not support this claim.
Potential worsening of hormone-dependent tumors due to initial gonadotropin surge
TheoreticalExtrapolated from GnRH agonist flare literature; no gonadorelin-specific evidence identified
Skin allergic reactions at pump infusion site (noted in pulsatile pump studies)
LowLutrepulse product monograph, adverse reactions and frequency table — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf
Interaction summary(8)
Rated by direction with this peptide
GnRH agonists and antagonists (leuprolide, goserelin, cetrorelix, ganirelix)
CautionModerateThese act at the same receptor - antagonists block it and agonists downregulate the gonadotroph - so co-administration abolishes or invalidates gonadorelin's LH/FSH response. The consequence is loss of effect or an uninterpretable diagnostic test, not direct toxicity. This is a mechanism-based inference, not a documented clinical interaction study.
Mechanism-based inference from GnRH-receptor pharmacology and GnRH agonist/antagonist labeling; no gonadorelin-specific interaction study identified
Exogenous sex steroids (androgens, estrogens, progestins, oral contraceptives)
CautionModeratePer the labeling, gonadotropin levels are suppressed by oral contraceptives, and medications containing androgens, estrogens, progestins or glucocorticoids should be avoided during gonadorelin testing, since negative feedback blunts the LH/FSH response and can produce a falsely abnormal result.
Factrel labeling — https://www.rxlist.com/factrel-drug.htm
Dopamine antagonists and phenothiazines (prolactin-raising agents)
CautionModeratePer the labeling, the gonadorelin response may be blunted by phenothiazines and dopamine antagonists that cause a rise in prolactin, since hyperprolactinemia suppresses gonadotroph responsiveness.
Factrel labeling — https://www.rxlist.com/factrel-drug.htm
Clomiphene citrate and other ovarian stimulants
CautionLowThe evidence is a single case. In 268 women in the pivotal Lutrepulse program, the one reported case of moderate ovarian hyperstimulation occurred with concomitant clomiphene citrate. Biologically plausible and worth monitoring when ovarian stimulants are used together.
Lutrepulse product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (1 case in 268 women, with concomitant clomiphene)
Spironolactone
CautionLowPer the labeling, gonadotropin levels may be transiently elevated by spironolactone, which can confound interpretation of a gonadorelin stimulation test. Diagnostic-interpretation issue only, not a safety interaction.
Factrel labeling — https://www.rxlist.com/factrel-drug.htm
Digoxin
CautionLowPer the labeling, gonadotropin levels may be suppressed by digoxin, potentially producing a blunted apparent response to gonadorelin. Diagnostic-interpretation issue only.
Factrel labeling — https://www.rxlist.com/factrel-drug.htm
Levodopa
CautionLowPer the labeling, gonadotropin levels may be minimally elevated by levodopa; the effect is small but relevant to diagnostic test interpretation.
Factrel labeling — https://www.rxlist.com/factrel-drug.htm
Glucocorticoids
CautionLowPer the labeling, preparations containing glucocorticoids (alongside androgens, estrogens and progestins) should be avoided during gonadorelin testing because they directly affect pituitary gonadotropin secretion. Diagnostic-interpretation issue only.
Factrel labeling — https://www.rxlist.com/factrel-drug.htm
Known risks(13)
Headache, nausea, lightheadedness, and abdominal discomfort (uncommon)
Injection site reactions including pain, swelling, induration, and pruritus
Hypersensitivity/anaphylactic reactions (rare but reported; caution on re-administration)
Flushing and tachycardia (rare)
Bronchospasm (rare)
Multiple pregnancy risk when used for ovulation induction (12% incidence in clinical trials)
Ovarian hyperstimulation syndrome (rare, especially with concurrent clomiphene)
Antibody formation with repeated administration (rare)
Risk of pituitary apoplexy if administered to patients with undiagnosed pituitary adenoma
Menorrhagia (frequency unknown)
Paradoxical pituitary downregulation with continuous (non-pulsatile) high-dose administration
Potential worsening of hormone-dependent tumors due to initial gonadotropin surge
Skin allergic reactions at pump infusion site (noted in pulsatile pump studies)
Drug interactions(10)
Androgens (testosterone, nandrolone, etc.)
Suppress pituitary gonadotropin secretion via negative feedback, reducing response to gonadorelin diagnostic test; therapeutic interaction is the basis for using gonadorelin as a TRT adjunct
Estrogens and oral contraceptives
Suppress gonadotropin levels and blunt the pituitary response to gonadorelin
Progestins
Directly affect pituitary gonadotropin secretion and may alter gonadorelin response
Glucocorticoids
Can suppress the hypothalamic-pituitary-gonadal axis, potentially reducing gonadorelin efficacy
Spironolactone
Transiently elevates gonadotropin levels, potentially enhancing gonadorelin response
Digoxin
Suppresses gonadotropin levels, reducing response to gonadorelin
Phenothiazines and dopamine antagonists
Cause elevated prolactin levels which blunt the pituitary response to gonadorelin
Levodopa
Minimally elevates gonadotropin levels
Clomiphene citrate
Concurrent use with gonadorelin for ovulation induction may increase risk of ovarian hyperstimulation syndrome
GnRH agonists/antagonists (leuprolide, goserelin, cetrorelix, degarelix)
Compete for or modulate GnRH receptors; concurrent use is contraindicated as it will interfere with gonadorelin action
Research & benefits
Evidence base
- Evidence Level
- Level 1-2 — Strong
- Total Studies
- Hundreds of published studies on GnRH physiology and clinical applications
- Human Studies
- Extensive human data from clinical trials, diagnostic use, and fertility treatment spanning 50+ years
Gonadorelin has decades of Level I-II evidence for ovulation induction in hypothalamic amenorrhea and spermatogenesis induction in hypogonadotropic hypogonadism. The diagnostic GnRH stimulation test is a well-validated clinical tool. Its use as an HCG alternative in TRT protocols is supported by mechanistic rationale and clinical experience but lacks large randomized controlled trials.
Researched for(6)
Rated by confidence in the evidence
Stimulates endogenous LH and FSH production
HighReproducible, dose-dependent LH and FSH rise in humans, basis of an FDA-approved diagnostic test.
Factrel (gonadorelin HCl) labeling summary via RxList — https://www.rxlist.com/factrel-drug.htm (indications and pharmacology) ; Lutrepulse (gonadorelin acetate) product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf
Induces ovulation in hypothalamic amenorrhea
HighApproved therapy; pulsatile dosing produced ovulation in about 94-96% of women in clinical trials.
Lutrepulse (gonadorelin acetate) product monograph, trial results — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (268 women, 94%/96% ovulation rates, 142 pregnancies)
Stimulates spermatogenesis in hypogonadotropic hypogonadism
MediumPulsatile GnRH pump therapy induced sperm production in about 61% of men in a 2024 study.
Arch Endocrinol Metab 2024, pulsatile GnRH for spermatogenesis after poor gonadotropin response — https://pmc.ncbi.nlm.nih.gov/articles/PMC11156179/ (17/28 = 60.7%); Reprod Biol Endocrinol 2025, pulsatile GnRH vs combined gonadotropin — https://link.springer.com/article/10.1186/s12958-025-01370-7
Diagnostic evaluation of pituitary function
MediumFDA-approved test to assess pituitary gonadotrope response, though it cannot pinpoint the cause alone.
Factrel (gonadorelin HCl) labeling summary — https://www.rxlist.com/factrel-drug.htm (indications)
Potential preservation of testicular function during TRT
SpeculativeNo published human trials; rationale relies on mechanism and analogy to hCG therapy.
No primary trial identified; claim rests on mechanism and hCG-analogy only
More physiologic hormonal stimulation than HCG
LowMechanistically plausible and suggested by non-randomized human data, but no head-to-head trial confirms it.
Lutrepulse product monograph, mechanism/comparison with hMG — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf ; Arch Endocrinol Metab 2024 — https://pmc.ncbi.nlm.nih.gov/articles/PMC11156179/ (greater testicular volume increase on pulsatile GnRH).
Benefits(6)
Stimulates endogenous LH and FSH production
Well-established mechanism confirmed in extensive clinical research since the 1970s; pulsatile release pattern differentially regulates LH (fast pulses) vs FSH (slow pulses)
Induces ovulation in hypothalamic amenorrhea
Multicenter clinical trial (Santoro 1990, PMID 2122733): 91% ovulation rate in primary amenorrhea, 96% in secondary amenorrhea among 109 women
Stimulates spermatogenesis in hypogonadotropic hypogonadism
Zhang et al. 2018 (PMC6775549): Pulsatile gonadorelin pump achieved 90% spermatogenesis rate with median onset of 6 months vs 14 months for gonadotropin therapy
Diagnostic evaluation of pituitary function
FDA-approved use (Factrel): A single bolus injection with serial LH measurements assesses pituitary gonadotrope responsiveness; the single-injection test cannot determine the cause of a subnormal response on its own.
Potential preservation of testicular function during TRT
Used in clinical practice as HCG alternative since 2020; evidence is mixed — may help reduce testicular atrophy but does not reliably maintain intratesticular testosterone in all patients
More physiologic hormonal stimulation than HCG
Works through natural HPG axis signaling rather than direct gonadal stimulation; produces more stable testosterone levels compared to gonadotropin therapy (Zhang et al. 2018)
Key studies(5)
Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection
Multicenter Clinical Trial109 womenMultiple ovulatory cyclesSantoro N
American Journal of Obstetrics and Gynecology
1990
Pulsatile GnRH achieved 91% ovulation in primary and 96% in secondary hypothalamic amenorrhea, with comparable efficacy to hMG and reduced risks
The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men
Prospective Comparative Study28 men (10 PGP, 18 CGT)24 monthsZhang L, Cai K, Wang Y, Ji W, Cheng Z, Chen G, Liao Z
American Journal of Men's Health
2018
Pulsatile gonadorelin pump induced spermatogenesis at median 6 months vs 14 months for cyclical gonadotropin therapy (p=0.01); 90% vs 83.3% spermatogenesis rates
Physiology, Gonadotropin-Releasing Hormone
Comprehensive ReviewN/A (review)Stamatiades GA, Kaiser UB (referenced); StatPearls comprehensive review
StatPearls / NCBI Bookshelf
2024
GnRH pulsatile secretion pattern differentially regulates LH (fast pulses) vs FSH (slow pulses); half-life 2-4 minutes; acts via Gq-coupled GnRHR activating PLC/IP3/DAG/PKC signaling cascade
Physiology of GnRH and Gonadotrophin Secretion
Comprehensive ReviewN/A (review)Marques P, et al.
Endotext / NCBI Bookshelf
2024
Comprehensive review of GnRH neurobiology, KNDy neuronal regulation (kisspeptin/neurokinin B/dynorphin), and clinical applications in reproductive medicine
Effectiveness and safety of pulsatile GnRH pump therapy on female patients with IHH
Clinical StudyFemale patients with idiopathic hypogonadotropic hypogonadismVariableVarious (Chinese study)
PubMed indexed study
2015
Pulsatile GnRH pump therapy demonstrated effectiveness and safety for inducing puberty and fertility in female IHH patients
What research suggests over time
Weeks 2-4
Decades of clinical usePulsatile dosing restores physiologic LH/FSH pulses; testicular volume or follicular development begins responding within days.
Months 2-3
Level I clinicalOvulation induction in 91% of women with primary hypothalamic amenorrhea (Am J Obstet 1990); follicular development on schedule.
Long-term
Level I clinicalPulsatile gonadorelin pump induced spermatogenesis at median 6 months in hypogonadotropic hypogonadism (vs 14 months for cyclical gonadotropin therapy).
Regulation & availability
Why researchers look at it
Surged in demand after HCG was reclassified as a biologic in 2020 and pulled from compounding pharmacies, leaving men on testosterone therapy without their primary fertility-preservation tool. Clinical evidence is strong for its core use — 91-96% ovulation success rates in women with hypothalamic amenorrhea — and growing clinical experience supports its newer role as an HCG substitute during TRT. Large randomized trials for the TRT application are still needed, but if confirmed, gonadorelin could become the standard adjunct in testosterone protocols nationwide.
- Estimated cost
- $50-150/mo compounding
- FDA status
- Human Factrel (gonadorelin hydrochloride, NDA 018123) was FDA-approved for diagnostic use in 1982; Lutrepulse Kit (gonadorelin acetate, NDA 019687) was approved in 1989 for pulsatile IV administration to induce ovulation in primary hypothalamic amenorrhea. Both are discontinued in the US, and no currently marketed FDA-approved human formulation exists. Compounded gonadorelin is not FDA-approved; 503A use must meet applicable statutory conditions, and gonadorelin acetate appears in 503B interim-policy Category 1. Veterinary gonadorelin products, including Factrel (NADA 139-237) and Fertagyl (ANADA 200-134), are approved for cattle. Gonadorelin is recognized by the FDA as a known substance (UNII registered: gonadorelin hydrochloride and gonadorelin acetate).
- WADA status
- PROHIBITED IN MALES — Gonadorelin (GnRH) and its agonist analogues are prohibited at all times under section S2.2.1 of the 2026 WADA Prohibited List, effective January 1, 2026. The listed examples include buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin. Athletes with a legitimate medical need may require a Therapeutic Use Exemption.
- Prescribability
- Yes — available through compounding pharmacies; branded products (Factrel, Lutrepulse) discontinued in the US
- Availability
- Branded products discontinued in the US: Factrel (gonadorelin HCl, diagnostic) and Lutrepulse (gonadorelin acetate, pulsatile fertility treatment) are no longer marketed. Currently available through US 503B outsourcing facilities and compounding pharmacies (e.g., Empower Pharmacy, Strive Pharmacy) as compounded gonadorelin for subcutaneous injection, prescribed off-label alongside testosterone therapy as an HCG alternative. Also available internationally: gonadorelin powder for injection (Esteve Pharmaceuticals, UK) for diagnostic use. Veterinary Factrel remains FDA-approved for use in cattle.
International status
EU
Available as prescription medication
US
Previously FDA-approved; available via compounding
Australia
Available via compounding
Regulatory timeline(7)
- 1977GnRH structure first characterized by Andrew Schally and Roger Guillemin (awarded Nobel Prize in Physiology or Medicine 1977)
- 1977Synthetic GnRH (gonadorelin) first produced for clinical research
- 1982Factrel (gonadorelin HCl) approved by FDA for diagnostic evaluation of pituitary gonadotrope function
- 1989Lutrepulse (gonadorelin acetate) approved by FDA for pulsatile IV administration to induce ovulation in primary hypothalamic amenorrhea
- 1999Both Factrel and Lutrepulse discontinued from US market due to limited commercial viability and complexity of pulsatile pump administration
- 2020-03FDA reclassifies HCG as a biologic product; compounding pharmacies can no longer produce HCG, driving adoption of compounded gonadorelin as an alternative in TRT protocols
- 2026Gonadorelin remains available through 503A/503B compounding pharmacies; no new FDA-approved human formulation. Continued inclusion on WADA Prohibited List (S2 category). Veterinary formulation (Fertagyl) remains FDA-approved for cattle.
Sources & FAQs
Research sources(10)
- https://pubmed.ncbi.nlm.nih.gov/2122733/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6775549/
- https://www.ncbi.nlm.nih.gov/books/NBK558992/
- https://www.ncbi.nlm.nih.gov/books/NBK279070/
- https://pubmed.ncbi.nlm.nih.gov/26813133/
- https://www.medicines.org.uk/emc/product/4853/smpc
- https://www.mayoclinic.org/drugs-supplements/gonadorelin-intravenous-route-injection-route/description/drg-20067426
- https://en.wikipedia.org/wiki/Gonadotropin-releasing_hormone
- https://www.empowerpharmacy.com/compound-medication/mens-health/compounded-gonadorelin-in-mens-health/
- https://www.wada-ama.org/en/prohibited-list
Frequently asked questions(6)
What is the difference between gonadorelin and HCG?
Gonadorelin (GnRH) works upstream in the hormonal axis — it stimulates the pituitary gland to release LH and FSH naturally, which then signal the testes. HCG mimics LH and directly stimulates the testes. Gonadorelin produces a more physiologic response but requires more frequent dosing than HCG and may be less potent at maintaining intratesticular testosterone levels.
Why did gonadorelin become popular as a TRT adjunct?
In 2020, the FDA reclassified HCG as a biologic product, which meant compounding pharmacies could no longer produce it. Gonadorelin emerged as the primary compounded alternative for men on TRT who wanted to preserve testicular function and fertility.
How is gonadorelin administered?
For diagnostic use: a single IV or SC injection. For fertility treatment (historical): pulses via programmable pump. For TRT adjunct (compounded): subcutaneous injection.
What is the half-life of gonadorelin?
Gonadorelin has an extremely short plasma half-life of approximately 2-4 minutes, with rapid hydrolysis into smaller peptide fragments. The distribution half-life is 2-10 minutes and terminal half-life is 10-40 minutes. This short half-life is why pulsatile pump delivery was developed for therapeutic use.
Is gonadorelin effective for maintaining fertility on TRT?
Evidence is mixed. While gonadorelin stimulates LH/FSH release through natural pathways, its very short half-life means a single daily injection may not provide sustained gonadotropin stimulation. Some clinicians report success in reducing testicular atrophy, but it does not reliably maintain sperm production in all men on TRT. Pulsatile pump delivery would be more physiologic but is impractical for most patients.
Can gonadorelin be used in women?
Yes. Gonadorelin has strong clinical evidence for inducing ovulation in women with hypothalamic amenorrhea (91-96% ovulation rates in clinical trials). It was historically administered via pulsatile pump (Lutrepulse) for this indication. It is also used diagnostically to evaluate pituitary function in both sexes.